{"nctId":"NCT01854528","briefTitle":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","startDateStruct":{"date":"2013-06"},"conditions":["Chronic Hepatitis C Infection"],"count":148,"armGroups":[{"label":"3-DAA/RBV","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267, ABT-333","Drug: Ribavirin"]},{"label":"TPV/RBV","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ribavirin","Drug: Pegylated Interferon a-2a (PegINF)","Drug: Telaprevir"]}],"interventions":[{"name":"ABT-450/r/ABT-267, ABT-333","otherNames":["ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ABT-333 also known as dasabuvir","Viekira PAK"]},{"name":"Ribavirin","otherNames":[]},{"name":"Pegylated Interferon a-2a (PegINF)","otherNames":[]},{"name":"Telaprevir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile\n* Chronic hepatitis C infection (positive for anti-HCV antibody or HCV RNA at least 6 months before screening and at the time of screening; or positive for anti-HCV antibody or HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection)\n* Screening laboratory result indicating HCV genotype 1 infection (HCV GT1)\n* Participant must have documentation of adherence to a prior pegIFN/RBV combination therapy and meet one of the protocol definitions for treatment failure: null responder, partial responder, relapser\n* No evidence of liver cirrhosis\n\nExclusion Criteria:\n\n* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody\n* Positive screen for drugs or alcohol\n* Significant sensitivity to any drug\n* Use of contraindicated medications within 2 weeks of dosing\n* Abnormal laboratory tests","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment","description":"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \\[HCV RNA\\] level less than the lower limit of quantitation \\[\\< LLOQ\\]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Final Treatment Visit in the Mental Component Summary (MCS) Score of the Short-Form 36 Health Survey - Version 2 (SF-36v2)","description":"The SF-36v2 is a general health-related quality of life (HRQoL) instrument with extensive use in multiple disease states. The SF-36v2 instrument comprises a total of 36 items (questions) targeting a participant's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Domain scores were aggregated into an MCS score (from 0 to 100; a higher score indicates better mental function and well-being).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"8.32"},{"groupId":"OG001","value":"-9.8","spread":"11.05"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Final Treatment Visit in the Physical Component Summary (PCS) Score of the Short-Form 36 Health Survey - Version 2 (SF-36v2)","description":"The SF-36v2 is a general health-related quality of life (HRQoL) instrument with extensive use in multiple disease states. The SF-36v2 instrument comprises a total of 36 items (questions) targeting a participant's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Domain scores were aggregated into a PCS score (range = 0 to 100; a higher score indicates better mental function and well-being).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"7.16"},{"groupId":"OG001","value":"-7.7","spread":"7.72"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment","description":"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \\[HCV RNA\\] level less than the lower limit of quantitation \\[\\< LLOQ\\]) 24 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure During Treatment","description":"Virologic failure during treatment was defined as HCV ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (≥ LLOQ) after HCV RNA \\< LLOQ during treatment or confirmed HCV RNA ≥ LLOQ at the end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Relapse After Treatment","description":"Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (\\<LLOQ) at the end of treatment were considered to have virologic relapse if they had confirmed HCV RNA ≥ LLOQ during the post-treatment period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["HEADACHE","PRURITUS","NAUSEA","ASTHENIA","FATIGUE"]}}}